Retatrutide targets three hormones instead of one, helping trial participants achieve unprecedented levels of weight-loss ...

Eli Lilly, a U.S. pharmaceutical company, announced that its next-generation obesity treatment under development achieved ...

Mounjaro and Zepbound are two brand-name glucagon-like peptide-1 (GLP-1) medications manufactured by Eli Lilly. Although they ...

As the number of users of obesity treatments increases, the competition for leadership over next-generation products is ...

Tirzepatide leads near-term, Retatrutide targets Class III, Foundayo expands maintenance—see 2030 sales & $1,300 PT.

An ex-Special Forces colonel tipped as a future prime minister has claimed almost £36,000 in taxpayer money for ...

The real goal is to lose excess fat while protecting muscle, strength, joint health, posture, balance, and metabolism.

Eli Lilly and Company today announced detailed results from two late-phase trials showing that people with obesity maintained their weight loss long term with either Foundayo or lower-dose Zepbound ...

THEY are arguably the biggest medical breakthrough of recent times, helping Brits to shed the pounds with barely any effort at all. So-called ‘fat jabs’ have had a surge of popularity and now, one ...

Diarrhea is one of the most common side effects of Mounjaro (tirzepatide), with rates increasing at higher doses. Most cases are mild and improve over time, but severe symptoms require prompt medical ...

Soon-to-be brides and grooms seeking ⁠short cuts to shed pounds before the big day have become the latest consumer target ⁠for weight-loss drugs in India. New Delhi wellness clinic Klarity Skin Clinic ...

Mounjaro’s dosage is gradually increased to allow the body to adapt to the medication and minimize potential side effects, ensuring a safe and effective treatment experience. The dosage escalation for ...